CEFTRIAXONE SODIUM FOR INJECTION BP POWDER FOR SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

CEFTRIAXONE (CEFTRIAXONE SODIUM)

可用日期:

SANDOZ CANADA INCORPORATED

ATC代码:

J01DD04

INN（国际名称）:

CEFTRIAXONE

剂量:

250MG

药物剂型:

POWDER FOR SOLUTION

组成:

CEFTRIAXONE (CEFTRIAXONE SODIUM) 250MG

给药途径:

INTRAMUSCULAR

每包单位数:

1ML(IM)-2.5ML(IV)

处方类型:

Prescription

治疗领域:

THIRD GENERATION CEPHALOSPORINS

產品總結:

Active ingredient group (AIG) number: 0117292001; AHFS:

授权状态:

APPROVED

授权日期:

2018-03-15

产品特点

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR CEFTRIAXONE SODIUM FOR INJECTION BP
Sterile Powder for Solution, 250 mg, 1 g, 2 g and 10 g ceftriaxone per
vial
Intravenous or Intramuscular
BP
Antibiotic
Sandoz Canada Inc.
110 Rue de Lauzon
Boucherville, (Québec), Canada
J4B 1K6
Date of Initial Authorization:
August 17, 2006
Date of Revision:
January 6, 2022
Submission Control Number: 255080
Ceftriaxone Sodium for Injection BP
Page 2 of 58
RECENT MAJOR LABEL CHANGES
7 Warnings and Precautions
01/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
TABLE OF CONTENTS
.................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
4
1
INDICATIONS.....................................................................................................................
4
1.1
P
EDIATRICS
.........................................................................................................................
5
1.2
G
ERIATRICS
.........................................................................................................................
5
2
CONTRAINDICATIONS
........................................................................................................
5
4
DOSAGE AND
ADMINISTRATION..........................................................................................
5
4.1
D
OSING
C
ONSIDERATI ONS
.......................................................................................................
5
4.2
R
ECOMMENDED
D
OSE AND
D
OSAGE
A
DJUSTMENT
...........................................................................
6
4.3
R
ECONSTI TUTI ON
..................................................................................................................
7
4.4
A
DMINISTRATION
.....................................................................................